Hancock Whitney Corp Sells 103,479 Shares of DexCom, Inc. (NASDAQ:DXCM)

Hancock Whitney Corp cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 94.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,312 shares of the medical device company’s stock after selling 103,479 shares during the period. Hancock Whitney Corp’s holdings in DexCom were worth $423,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of DXCM. Blue Whale Capital LLP grew its stake in DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after purchasing an additional 113,000 shares during the period. Harvest Fund Management Co. Ltd grew its position in DexCom by 53.4% during the third quarter. Harvest Fund Management Co. Ltd now owns 18,459 shares of the medical device company’s stock valued at $1,237,000 after buying an additional 6,425 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in DexCom during the third quarter worth about $961,000. Fisher Asset Management LLC raised its position in DexCom by 10.6% in the third quarter. Fisher Asset Management LLC now owns 856,124 shares of the medical device company’s stock worth $57,395,000 after acquiring an additional 82,250 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in DexCom by 0.6% in the third quarter. Daiwa Securities Group Inc. now owns 77,099 shares of the medical device company’s stock worth $5,169,000 after acquiring an additional 490 shares during the period. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on DXCM. Wells Fargo & Company raised their price target on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Raymond James lowered their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Price Performance

DXCM stock opened at $78.10 on Thursday. The firm has a 50 day simple moving average of $71.11 and a two-hundred day simple moving average of $88.51. The stock has a market cap of $30.51 billion, a PE ratio of 46.77, a P/E/G ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,431 shares of company stock worth $399,319. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.